UPMC Physician Resources

Research Study Available for Older Adults Living with Low Back Pain and Depression

PITTSBURGH, May 8, 2014 – Older adults experiencing chronic low back pain and depression are invited to participate in the final year of a five-year study that aims to find out whether medication alone or medication along with health coaching and learning new problem-solving skills is best for treating both conditions. The “Addressing Depression and Pain Together,” or ADAPT study, is an effort led by researchers at the University of Pittsburgh School of Medicine.

Both low back pain and clinical depression are common in seniors, and up to 25 percent of older adults suffer from both conditions at the same time, said principal investigator Jordan F. Karp, M.D., associate professor of psychiatry, University of Pittsburgh School of Medicine.

“Chronic low back pain and depression make each other worse, have similar risk factors, and increase the likelihood of each other’s recurrence,” he said. “Both can cause poor sleep and subsequent daytime drowsiness, keep people from participating or enjoying their usual activities, and isolate them at home. When they are both present, patients can enter a vicious cycle of the blues, pain, physical deconditioning, and feeling hopeless.”

For the ADAPT study, adults 60 or older who have depression symptoms and  low back pain on most days for at least three months will participate in the first stage during which everyone takes  the anti-depressant drug venlafaxine, also known as Effexor. Participants who have not improved after the first six weeks then have the opportunity to continue in the study for an additional 14 weeks, and be randomly assigned to receive a higher dose of venlafaxine alone or in combination with a counseling program that teaches problem-solving skills specific for managing pain, mood, sleep, and other difficulties commonly experienced by seniors living with these linked conditions.

At low doses, venlafaxine increases the levels of the neurotransmitter serotonin, which regulates mood. At higher doses, the drug also increases levels of the neurotransmitter norepinephrine, which regulates both mood and pain, Dr. Karp said.

“Venlafaxine has been approved for the treatment of anxiety and depression, and it is a widely used, well-tolerated drug,” he said. “Getting people moving and in better control of their pain through healthy behavior changes also may help their mood and improve quality of life.”

According to Dr. Karp, the goal of the study is to learn whether people who do not improve with low-dose venlafaxine alone need the addition of the problem-solving therapy to get them feeling better.

For more information about participating in the study, which is sponsored by the National Institutes of Health, call 412-246-6015 or visit www.ADAPTstudy.com.

Children’s Hospital of Pittsburgh of UPMC Researcher Receives Prestigious Research Award

PITTSBURGH, May 5, 2014 – The Academic Pediatric Association (APA) has awarded Alejandro Hoberman, M.D., chief, Division of General Academic Pediatrics at Children’s Hospital of Pittsburgh of UPMC, its 2014 APA Research Award. The award will be presented today at the Pediatric Academic Societies (PAS) annual meeting in Vancouver, British Columbia, Canada.

The award acknowledges his contributions toward advancing pediatric knowledge through excellence in research, originality, creativity and methodological soundness. Dr. Hoberman is known for his research on acute otitis media (AOM) and urinary tract infections (UTI).

The quality and influence of Dr. Hoberman’s research is evident from the journals in which they are published, including the New England Journal of Medicine (NEJM), Journal of the American Medical Association (JAMA), JAMA Pediatrics, and Pediatrics. He has served on the National Institutes of Health (NIH) special emphasis panels, NIH strategic planning workgroups, American Academy of Pediatrics guideline committees, and as a member of the Clinical and Translational Science Award Child Health Oversight Committee.

Dr. Hoberman graduated from medical school in Buenos Aires, Argentina, where he completed a general pediatrics residency at the Children’s Hospital of Buenos Aires. He then came to the United States for fellowship training in ambulatory pediatrics at Children’s Hospital of Pittsburgh under Jack L. Paradise, M.D., and Kenneth Rogers, M.D. Immediately following the fellowship, he joined the faculty at the University of Pittsburgh School of Medicine and Children’s Hospital of Pittsburgh of UPMC, and currently leads the Division of General Academic Pediatrics. In 2000, Dr. Hoberman was named the first Jack L. Paradise, M.D., Professor of Pediatric Research at Children’s.

“Everything goes back to what I learned from Dr. Paradise, who received the APA Research Award 20 years ago,” Dr. Hoberman said. “I remember watching him take great care with research participants to conduct a careful examination, and sitting with families to discuss clinical findings and how we were trying to learn how to provide better, evidenced-based care for their children and future generations of children. That personal touch and connection with families, which Dr. Paradise taught by example, enables trust and the understanding that the research team will always have the participant’s best interest in mind and provide the most comprehensive and careful medical care.”

“It was apparent soon after Dr. Hoberman’s arrival at Children’s that he had great promise,” said Jack L. Paradise, M.D., Professor Emeritus of Pediatrics, University of Pittsburgh School of Medicine. “He has more than met expectations, conducting important research while at the same time building one of the country’s strongest divisions of academic general pediatrics and serving as a role model for pediatric trainees at all levels. He richly deserves this prestigious award.”

In addition to receiving the award in Vancouver, Dr. Hoberman presented the results of his multi-center study showing how prophylactic antibiotics prevent urinary tract infection recurrences in children with vesicoureteral reflux.

For more information on Dr. Hoberman and Children’s Hospital of Pittsburgh of UPMC, visit www.chp.edu.

Children’s Hospital of Pittsburgh of UPMC Expert Shows Prophylactic Antibiotics Prevent Urinary Tract Infection Recurrences in Children with Vesicoureteral Reflux

VANCOUVER, BRITISH COLUMBIA, CANADA, May 4, 2014 – A study led by researchers at Children’s Hospital of Pittsburgh of UPMC demonstrated that children diagnosed with an abnormal flow of urine from the bladder to the upper urinary tract, called vesicoureteral reflux (VUR), can avoid recurrent urinary tract infections (UTI) by taking daily low-dose antibiotics, although the treatment didn’t reduce their risk for UTI-induced kidney scarring. The results of the multi-center study will be presented today at the Pediatric Academic Societies (PAS) annual meeting in Vancouver, British Columbia, Canada. The study also is published in the New England Journal of Medicine.

“Our study provides a clear message that recurrences of UTI in children with vesicoureteral reflux can be prevented, some of these children appear pretty sick when they have a UTI with fever,” said Alejandro Hoberman, M.D., chief, Division of General Academic Pediatrics at Children’s Hospital of Pittsburgh. “VUR is present in one-third of children presenting with UTI accompanied by a fever and has been associated with a heightened risk of kidney scarring. One way to decrease infection risk is to give children antibiotics when they are well, called antimicrobial prophylaxis.”

Earlier randomized, controlled trials that compared anti-reflux surgery with antimicrobial prophylaxis showed no differences in rates of recurrent UTIs and renal scarring; however, the actual efficacy of either treatment could not be determined because the studies lacked a placebo or observation comparison groups. Recently conducted randomized trials have reported conflicting results about the effectiveness of antimicrobial prophylaxis in reducing recurrences.

“This study showed unequivocal evidence that antimicrobial prophylaxis reduced at least in half the likelihood of children having recurrent UTIs,” said Dr. Hoberman, also professor of pediatrics at the University of Pittsburgh School of Medicine. “Some subgroups of children derived the most benefit, particularly those with bladder and bowel dysfunction at baseline, and those in whom the UTI occurred with fever.”

The goal of the two-year study was to determine if giving children low-dose trimethoprim-sulfamethoxazole would prevent recurrent UTIs, decrease kidney scarring and contribute to the emergence of bacterial resistance.

The study, named the Randomized Intervention for Children with Vesicoureteral Reflux (RIVUR) Trial, enrolled 607 children ages 2 to 71 months who were diagnosed with VUR following a first or second episode of UTI. Participants were recruited from 19 clinical trial centers in the United States and underwent kidney scans to determine if scarring was present. They were then randomized to receive trimethoprim-sulfamethoxazole or a placebo. Kidney scans were repeated at one and two years after study entry.

Results showed that 39 of 302 children (13 percent) receiving antimicrobial prophylaxis developed UTIs compared to 72 of 305 (24 percent) receiving placebo. Antimicrobial prophylaxis reduced the risk of infections by 50 percent compared with placebo.

“Rates of renal scarring at the outcome visit were low and not reduced by prophylaxis, perhaps because most children were enrolled after their first infection and because parents, instructed to be vigilant, sought early medical attention,” said Dr. Hoberman. “Not unexpectedly, recurrences that did occur in children who received prophylaxis were more likely to have been caused by a resistant pathogen.”

This research was supported by grants U01 DK074059, U01 DK074053, U01 DK074082, U01 DK074064, U01 DK074062, U01 DK074063 from the National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Department of Health and Human Services. This trial also was supported by the University of Pittsburgh Clinical and Translational Science Award (UL1RR024153 and UL1TR000005) and the Children’s Hospital of Philadelphia Clinical and Translational Science Award (UL1TR000003) both from the National Center for Research Resources, now at the National Center for Advancing Translational Sciences, National Institutes of Health.

For more information on Dr. Hoberman and Children’s Hospital of Pittsburgh of UPMC, visit www.chp.edu.

UPMC Physician Reaches Rare Milestone with 3000th Prostate Surgery

PITTSBURGH, May 1, 2014 Joel B. Nelson, M.D., chair of the Department of Urology at UPMC, has performed 3,000 radical prostatectomies since coming to Pittsburgh in 1999. He joins only a handful of surgeons in the world to reach this milestone.

Prostate cancer is the second most common cancer in American men, after skin cancer, with several treatments available for the disease. But often men shy away from surgical treatment because they believe it will leave them incontinent and impotent. Nerve-sparing radical prostatectomy is one of the most effective treatments because the cancer can be removed without harming nerves that control erections.

“The nerve-sparing approach not only removes the cancer but lowers the risk of impotence and bladder control problems, providing a better quality of life for the patient,” said Dr. Nelson. “Our vast experience distinguishes us from other programs and that helps give patients peace of mind when they seek treatment.”

Dr. Nelson has gained considerable recognition for both his clinical work and research. He has been featured in several publications due to the great strides he has made in the treatment of prostate cancer and is the recipient of multiple awards.

“We have seen remarkable results over the past decade. Currently, about 95 percent of patients undergo a bilateral nerve-sparing procedure with a prostate cancer-specific survival rate of 99.3 percent at five years and 98 percent at 10 years,” Dr. Nelson said.

Dr. Nelson also serves on the editorial boards for several scientific journals, including The Journal of Urology, and is an ad hoc reviewer for several other medical publications, including The New England Journal of Medicine.

UPMC East to Become Newest Site for UPMC Rehabilitation Institute

PITTSBURGH, May 1, 2014 – Construction is set to begin today on a new, 20-bed UPMC Rehabilitation Institute that is scheduled to open July 1 on the remodeled 6 East wing at UPMC East. It will mark the first Rehabilitation Institute location in Pittsburgh’s east-northeast corridor, complementing the current east-southeast location at UPMC McKeesport.

The facility will mark the ninth UPMC Rehabilitation Institute location as part of the system’s in-hospital network that provides specialized inpatient care for people needing physical, occupational and speech therapy after strokes or brain injuries, spinal cord injuries, various surgeries and other conditions. Children’s Hospital of Pittsburgh of UPMC also opened a Rehabilitation Institute this past winter. UPMC St. Margaret reopened its refurbished rehab unit in November, doubling its capacity to 26 beds.

“We are meeting a community need, in the area where our patients live,” said Mark Sevco, president of UPMC East. “It’s very exciting for us to open this in the eastern suburbs under the inpatient care of the Rehabilitation Institute. Utilizing existing space in a hospital that is very much in growth mode, just short of celebrating its second birthday, is a positive step for us. We continue to move forward with new clinical care.”

UPMC East recently was accredited by the independent Joint Commission as a primary stroke center. Stroke patients are expected to be among those receiving care at its new Rehabilitation Institute. Peter Hurh, M.D., specialist in inpatient rehabilitation and assistant professor in the Department of Physical Medicine and Rehabilitation at the University of Pittsburgh School of Medicine, will serve as the medical director of the new UPMC East location. This Rehabilitation Institute will bring at least 15 new hires to the community, among them full-time nurses, therapists, care managers, liaisons and more.

“There clearly is a need for more quality in-hospital rehabilitation units,” said Dr. Hurh. “We hope to address that need by opening this new unit at UPMC East, and bringing the Rehabilitation Institute’s experience and expertise to the eastern suburbs and beyond.”

“In the past year, we opened 12 new beds at a remodeled UPMC St. Margaret unit, Children’s came on line, and now we’re launching this new unit at UPMC East,” said Tim Kagle, executive director, UPMC Rehabilitation Network. “UPMC is growing in rehabilitation and showing both clinical quality and community success providing the care that people want and need in the neighborhoods and the areas where they live.”

Construction is considered to be relatively simple, hence it is scheduled to require barely two months. The primary focus of the work will entail the transformation of the waiting room, known as The Wedge, into a therapy gym, where such new equipment as a Lite Gait – a body-weight supporting gait system – will be part of the therapeutic curriculum. A multi-purpose room also will become the Activities for Daily Living unit.

Regenerative Medicine Improves Muscle Strength and Function in Leg Injuries, Pitt Study Shows

PITTSBURGH, April 30, 2014 – Damaged leg muscles grew stronger and showed signs of regeneration in three out of five men whose old injuries were surgically implanted with extracellular matrix (ECM) derived from pig bladder, according to a new study conducted by researchers at the University of Pittsburgh School of Medicine and the McGowan Institute for Regenerative Medicine. Early findings from a human trial of the process and from animal studies were published today in Science Translational Medicine.

When a large volume of muscle is lost, typically due to trauma, the body cannot sufficiently respond to replace it, explained senior investigator Stephen F. Badylak, D.V.M., Ph.D., M.D., professor of surgery at Pitt and deputy director of the McGowan Institute, a joint effort of Pitt and UPMC. Instead, scar tissue can form that significantly impairs strength and function.

Pig bladder ECM has been used for many years as the basis for medical products for hernia repair and treatment of skin ulcers. It is the biologic scaffold that remains left behind after cells have been removed. Previous research conducted by Dr. Badylak’s team suggested that ECM also could be used to regenerate lost muscle by placing the material in the injury site where it signals the body to recruit stem and other progenitor cells to rebuild healthy tissue.

“This new study is the first to show replacement of new functional muscle tissue in humans, and we’re very excited by its potential,” Dr. Badylak said. “These are patients who can’t walk anymore, can’t get out of a car, can’t get up and down from a chair, can’t take steps without falling. Now we might have a way of helping them get better.”

For the Muscle Tendon Tissue Unit Repair and Reinforcement Reconstructive Surgery Research Study, which is sponsored by the U.S. Department of Defense and is continuing to enroll new participants, five men who had at least six months earlier lost at least 25 percent of leg muscle volume and function compared to the uninjured limb underwent a customized regimen of physical therapy for 12 to 26 weeks until their function and strength plateaued for a minimum of two weeks.

Then, study lead surgeon J. Peter Rubin, M.D., UPMC Professor and chair of plastic surgery, Pitt School of Medicine, surgically implanted a “quilt” of compressed ECM sheets designed to fill into their injury sites. Within 48 hours of the operation, the participants resumed physical therapy for up to 26 additional weeks.

The researchers found that three of the participants, two of whom had thigh injuries and one a calf injury, were stronger by 20 percent or more six months after the surgery. One thigh-injured patient improved on the “single hop test” by 1,820 percent, and the other had a 352 percent improvement in a chair lift test and a 417 percent improvement in the single-leg squat test. Biopsies and scans all indicated that muscle growth had occurred. Two other participants with calf injuries did not have such dramatic results, but both improved on at least one functional measure and said they felt better.

“This work represents an important step forward in our ability to repair tissues and improve function with materials derived from natural proteins. There will be more options to help our patients,” Dr. Rubin said.

“We think it’s remarkable that this approach was able to improve function among patients who were all well past the acute injury response phase and were not helped by the standard surgical procedures they had already had,” Dr. Rubin said.

The study also showed six months after an injury, mice treated with ECM showed signs of new muscle growth while untreated mice appeared to form typical scars.

The research team includes lead authors Dr. Rubin and Brian M. Sicari, Ph. D., and others from Pitt and the McGowan Institute for Regenerative Medicine. The project was supported by research grants from the U.S. Department of the Interior; and National Institutes of Health grants AG042199 and HL76124-6.

For more information about the trial, which aims to enroll 40 participants, go to http://www.mirm.pitt.edu/badylak/clinical/muscle.asp or call 412-624-5308.

The U.S. Department of Defense’s Limb Salvage and Regenerative Medicine Initiative and the Muscle Tendon Tissue Unit Repair and Reinforcement Reconstructive Surgery Research Study is collaboratively managed by the Office of the Secretary of Defense. The Initiative is focused on rapidly and safely transitioning advanced medical technology in commercially viable capabilities to provide wounded warriors the safest and most advanced care possible today.

Low Cholesterol in Immune Cells Tied to Slow Progression of HIV

PITTSBURGH, April 29, 2014 – People infected with HIV whose immune cells have low cholesterol levels experience much slower disease progression, even without medication, according to University of Pittsburgh Graduate School of Public Health research that could lead to new strategies to control infection.

The Pitt Public Health researchers found that low cholesterol in certain cells, which is likely an inherited trait, affects the ability of the body to transmit the virus to other cells. The discovery, funded by the National Institutes of Health (NIH), is featured in today’s issue of mBio, the journal of the American Society for Microbiology.

When HIV enters the body, it is typically picked up by immune system cells called dendritic cells, which recognize foreign agents and transport the virus to lymph nodes where it is passed to other immune system cells, including T cells. HIV then uses T cells as its main site of replication. It is through this mechanism that levels of HIV increase and overwhelm the immune system, leading to AIDS. Once a person develops AIDS, the body can no longer fight infections and cancers. Prior to effective drug therapy, the person died within one to two years after the AIDS diagnosis.

“We’ve known for two decades that some people don’t have the dramatic loss in their T cells and progression to AIDS that you’d expect without drug therapy,” said lead author Giovanna Rappocciolo, Ph.D., an assistant professor at Pitt Public Health. “Instead the disease is much slower to progress, and we believe low cholesterol in dendritic cells may be a reason.”

The discovery was made possible by using 30 years of data and biologic specimens collected through the Pitt Men’s Study, a confidential research study of the natural history of HIV/AIDS, part of the national NIH-funded Multicenter AIDS Cohort Study (MACS).

“We couldn’t have made this discovery without the MACS. Results like ours are the real pay-off of the past three decades of meticulous data and specimen collection,” said senior author Charles Rinaldo, Ph.D., chairman of Pitt Public Health’s Department of Infectious Diseases and Microbiology, and professor of pathology. “It is thanks to our dedicated volunteer participants that we are making such important advances in understanding HIV, and applying it to preventing and treating AIDS.”

Medications called combination antiretroviral therapy (ART) disrupt the viral replication process and can delay the onset of AIDS by decades.

However, even without taking ART, a small percentage of people infected with HIV do not have the persistent loss of T cells and increase in levels of HIV after initial infection. They can sometimes go many years, even more than a decade, without the virus seriously compromising the immune system or leading to AIDS.

Through the Pitt Men’s Study/MACS, eight such “nonprogressors” were assessed twice a year for an average of 11 years and compared to eight typically progressing HIV-positive counterparts.

Dr. Rappocciolo and her colleagues found that in nonprogressors, the dendritic cells were not transferring the virus to T cells at detectible levels. When taking a closer look at these dendritic cells, the researchers discovered that the cells had low levels of cholesterol, even though the nonprogressors had regular levels of cholesterol in their blood. A similar finding was shown for B lymphocytes, which also pass HIV to T cells, leading to high rates of HIV replication.

Cholesterol is an essential component of the outer membranes of cells. It is required for HIV to replicate efficiently in different types of cells. None of the study participants were taking statins, which are cholesterol-lowering medications that some people take to prevent vascular problems when cholesterol in their blood is too high.

When HIV was directly mixed with the nonprogressors’ T cells in the laboratory, those T cells became infected with the virus at the same rate as the T cells of the regularly progressing, HIV-positive participants. Indeed, T cells from the nonprogressors had normal levels of cholesterol.

“This means that the disruption is unlikely to be due to a problem with the T cells, further supporting our conclusion that the slow progression is linked to low cholesterol in the dendritic cells and B cells,” said Dr. Rappocciolo.

“What is most intriguing is that dendritic cells in the nonprogressors had this protective trait years before they became infected with HIV,” Dr. Rinaldo said. “This strongly suggests that the inability of their dendritic cells and B cells to pass HIV to their T cells is a protective trait genetically inherited by a small percentage of people. Understanding how this works could be an important clue in developing new approaches to prevent progression of HIV infection.”

Additional researchers on this study are Mariel Jais, B.S., Paolo Piazza, Ph.D., Todd A. Reinhart, Sc.D., Stella J. Berendam, B.S., Laura Garcia-Exposito, Ph.D., and Phalguni Gupta, Ph.D., all of Pitt Public Health.

This research was supported by NIH grants U01-AI35041 and R37-AI41870.

Children’s Epilepsy Monitoring Unit Conducting Remote EEG Monitoring

PITTSBURGH, April 25, 2014 – The Epilepsy Monitoring Unit (EMU) at Children’s Hospital of Pittsburgh of UPMC has begun conducting remote video monitoring of newborns in the Neonatal Intensive Care Unit at Magee-Womens Hospital of UPMC. Electroencephalographic (EEG) video monitoring began in early 2014, and since then, the EMU has monitored four babies at Magee.

The EMU team at Children’s can visually monitor babies, at the request of the Magee NICU, through a camera installed at their bedsides.

The EMU now performs outpatient EEG testing at Children’s East in addition to Children’s Pine Center and Children’s South.

UPCI Awarded Nearly $10 Million in Prestigious NCI Grants to Foster Cancer Research

PITTSBURGH, April 24, 2014 – The University of Pittsburgh Cancer Institute (UPCI) has been awarded two highly sought-after grants from the National Cancer Institute (NCI), totaling nearly $10 million, that will aid in bringing the latest research developments from bench to bedside and accelerate research into such things as rare tumors. UPCI is one of only 12 centers in the country to receive the NCI Experimental Therapeutics-Clinical Trials Network with Phase I Emphasis grant and the only center in Pennsylvania to receive a Lead Academic Participating Site (LAPS) grant under the NCI’s new clinical trials network.

That’s good news to patients like Patrick Jackson, who was diagnosed with a rare cancer known as grade I myxopapillary-ependymomas a few years ago. Jackson was referred to UPMC, where doctors treat just a couple of cases like his each year. He said any developments that can speed research and help cancer patients is a good thing.

“I am so fortunate that my ependymoma is low grade and has responded so well to treatment,” Jackson said. “I would just want people to know that there is hope, and there is nothing more comforting than having doctors familiar with your disease.”

The awards are further evidence of UPCI’s place as one of the premier academic cancer research centers in the country. UPCI is the only NCI-designated comprehensive cancer center in western Pennsylvania and through the network of its clinical partner, UPMC CancerCenter, enables several thousand patients to participate in clinical trials each year.

“Participating in a clinical trial is the optimal form of therapy for patients who are willing and able and allows us to learn something for the future along the way. We are grateful for the support of our patients and providers who have been an integral part of our success and helped us attain these two very important awards,” said Nancy E. Davidson, M.D., director of UPCI and the UPMC CancerCenter.

The NCI Experimental Therapeutics-Clinical Trials Network with Phase I Emphasis grant is led by UPCI Deputy Director Edward Chu, M.D. The $4.25 million, five-year grant funds complex research into new drug therapies.

“Our focus is on developing completely novel agents and combination regimens. We also are trying to understand how some of these new targeted therapies work and how we can apply science to individually tailor these new treatments to specific cancers,” Dr. Chu said.

UPCI is uniquely qualified to lead efforts in drug development because of the team approach that goes into the research, he noted, with expertise in pharmacokinetics, pharmacodynamics and basic science.

“We have a large patient base that allows us to do these novel first-in-man studies. The large majority of the patients who are referred to us have failed standard-of-care therapies, and they are looking for new treatments. There is only a small handful of cancer centers across the country that can offer the types of phase I clinical studies available to our patients here in Pittsburgh and the western Pennsylvania region,” Dr. Chu said.

The LAPS grant is part of the new National Clinical Trials Network (NCTN), designed to speed up the time it takes research to get from the lab to patients through technological advances and enhanced cooperation. The nearly $5 million award is led by Adam Brufsky, M.D., Ph.D., UPCI’s associate director for clinical investigation. The grant will fund the costs of maintaining a clinical trials infrastructure that permits patients to enroll in national trials led by the NCTN at more than a dozen sites across the UPMC CancerCenter network.

“This grant is tremendous validation from the NCI about the important and cutting-edge work that we are doing here at UPCI and our ability to shape what’s happening in cancer research across the country. We’re excited to play a vital role in this new system and expand access to trials all over western Pennsylvania,” Dr. Brufsky said.

As part of the award, Dr. Brufsky will lead a group at UPCI that includes Dwight E. Heron, M.D., Mark Socinski, M.D.; John Kirkwood, M.D., and Robert P. Edwards, M.D.

The NCTN replaces the cooperative networks that existed previously and were based on a model developed more than half a century ago. NCI officials hope to speed research through improvements in data management infrastructure, the development of a standardized process for prioritization of new studies, consolidation of its component research groups to improve efficiency, and the implementation of a unified system of research subject protection at over 3,000 clinical trials sites.

One important outcome of this new network will be the ability to facilitate the conduct of trials in rare tumors where patient accrual has always been very difficult. The availability of a national network of clinical trials sites to locate and enroll patients with unusual cancers should enhance the feasibility of conducting such studies. Also, as more cancers are molecularly defined and classified into smaller subsets, the new network structure will support the molecular screening studies needed to define and locate the smaller groups of patients who might be eligible for such studies.

“It has always been our mission at UPMC CancerCenter to provide the best care possible to patients in their own communities, and this grant enhances our ability to do that,” Dr. Davidson said.

UPMC Orthopaedic Surgeon to Co-Direct AAOS Course on Preparing for Healthcare Reform

PITTSBURGH, April 22, 2014 – The American Academy of Orthopaedic Surgeons (AAOS) is hosting Shifting Volume to Value: Preparing your Practice for Healthcare Reform June 5–6, 2014 in Washington, D.C.

Now in its third year, this course offers practical tools for success in a changing health care environment. Experts who shape health care policy will present on the value-based shifts in health care reform as they relate to orthopaedic practices. Orthopaedic surgeons, hospital administrators, medical directors, service line managers, quality managers, government or regulatory officials, healthcare purchasers, payers, or insurance executives, orthopaedic practice executives, and healthcare policy community members are encouraged to attend.

Anthony M. DiGioia III, MD, medical director of the Bone and Joint Center at Magee-Womens Hospital of UPMC, will co-direct this two-day course with Kevin J. Bozic, MD, MBA, from UCSF Medical Center.

Page 10 of 50:« First« 7 8 9 10 11 12 13 »Last »